ACE2 in Amino Acid Transport and Tissue Physiology

Although angiotensin-converting enzyme 2 became a household name as the cellular receptor exploited by SARS-CoV-2 and as a counter-regulator of the renin–angiotensin system, those two well-covered angles represent only a fraction of what this remarkable enzyme does. Long before the pandemic, ACE2 was recognized as a zinc-dependent carboxypeptidase with an unusually broad substrate repertoire and an unexpected second life as a chaperone for amino acid transporters. This review deliberately looks past the viral-entry and blood-pressure narratives to examine ACE2 as an endogenous metabolic and structural protein: how it is built, how it shuttles neutral amino acids across the gut and kidney, where it sits in the body at single-cell resolution, how its surface levels are controlled after translation, and how its expression tracks with cardiovascular, metabolic, and malignant disease. Understanding these dimensions matters because they explain why ACE2 is expressed precisely where it is, why its abundance fluctuates with age and sex, and how its biology might be leveraged without touching the angiotensin cascade at all.

ACE2 and the Amino Acid Transporter Complex

The most distinctive non-cardiovascular role of ACE2 is its partnership with neutral amino acid transporters. ACE2 forms a stable heterodimer with B0AT1 (SLC6A19) in the gut and with the related imino-acid transporter SIT1 (SLC6A20) in the kidney, acting as an obligate chaperone that escorts these transporters to the plasma membrane and sets their surface abundance. Cryo-EM structures of the ACE2–B0AT1 and ACE2–SIT1 complexes bound to their native substrates — glutamine, methionine, and proline respectively — have revealed how the peptidase domain cradles the transporter and how substrate binding is accommodated at atomic resolution. The physiological stakes are high: loss of ACE2 or mutation of SLC6A19 produces Hartnup disease, a disorder of neutral amino acid malabsorption in the intestine and kidney, while defects in SLC6A20 cause iminoglycinuria. Intriguingly, ACE2's role in tryptophan transport in the gut intersects with glucose homeostasis under metabolic stress, positioning the enzyme at a previously unappreciated node linking amino acid absorption, microbial metabolite production, and systemic metabolism. This transporter-chaperone identity is the clearest reason ACE2 is so abundant on enterocytes: it is, in part, a nutrient-uptake machine.

ACE2 Post-Translational Regulation and Shedding

Because ACE2's surface abundance dictates both its enzymatic output and its availability as a binding partner, cells tightly control the protein after it is made. A C-terminal PDZ-recognition motif tethers ACE2 to the scaffold protein NHERF1 at the plasma membrane, stabilizing surface expression, while the E3 ubiquitin ligase Nedd4-2 marks C-terminal lysines for ubiquitination and degradation, particularly under angiotensin II stimulation. At the promoter level, the repressive histone mark H3K27me3 deposited by EZH2 keeps basal transcription in check. A further layer of control is shedding: the transmembrane metalloprotease ADAM17 cleaves the collectrin-like stalk of ACE2, releasing a soluble ectodomain into the extracellular space. This soluble fragment retains catalytic activity yet lacks membrane anchoring, and its circulating levels are shaped by inflammatory cues that activate ADAM17. Shedding therefore converts a anchored enzyme into a diffusible one, with consequences for local peptide turnover and for the proteolytic landscape of inflamed tissue. These post-translational circuits mean that ACE2 activity at any moment reflects a balance of tethering, ubiquitination, epigenetic silencing, and proteolytic release rather than simply how much mRNA is present.

ACE2 in Cancer

A growing body of oncology literature treats ACE2 less as a viral portal and more as a tissue-specific biomarker and modulator of the tumor microenvironment. Pan-cancer analyses drawing on public sequencing repositories show that ACE2 expression varies widely across malignancies: elevated in renal and hepatic tumors, reduced in lung adenocarcinoma, with context-dependent links to patient survival. In breast cancer, lower ACE2 expression correlates with aggressive features and may suppress progression through effects on matrix metalloproteinase activity, whereas in colorectal cancer, higher ACE2 protein associates with pathology type and PD-L1 positivity and performs reasonably well at discriminating tumor from non-tumor tissue. The mechanistic thread appears to be immune infiltration and angiogenesis: ACE2 levels track with the abundance of B cells, CD8+ T cells, macrophages, and dendritic cells in several cancers, suggesting the enzyme shapes the local immune landscape. Whether ACE2 acts predominantly as a tumor suppressor or a context-specific passenger remains unresolved, but its consistent association with immune signatures makes it an attractive candidate for stratification rather than a simple onco-gene.

Future of ACE2 Research

The next decade of ACE2 science will likely move even further from the pandemic framing. Atomic structures of the transporter complexes now invite small-molecule probes that tune ACE2's chaperone or catalytic functions without engaging the angiotensin system. The sheddase axis — ADAM17 and its regulators — offers a druggable route to shift the membrane-bound versus soluble balance in fibrosis, renal disease, and metabolic syndrome. In oncology, prospective validation of ACE2 as an immune-stratification marker is overdue. Perhaps most intriguingly, the enzyme's dual identity as peptidase and transporter chaperone suggests that nutrient status, the gut microbiome, and ACE2 abundance form a regulatory loop that has been obscured by the focus on blood pressure and viral entry. Decoupling ACE2 research from those two dominant narratives is not merely academic; it is where the genuinely new biology — and the untapped therapeutic opportunities — now live.

ACE2 ELISA Kits

ACE2 Antibodies

ACE2 Antigens